About the Project |  FAQs |  Glossary |  Data Sources |  Bibliography |  Complete Indicator List

Indicator Details: CKD Prevalence by Hypertension Statusa
Data Sources
Stratification and Year Choices:


  View Data By:
  Chart Format

  Chart Colors

Select a state from the dropdown below


Filter By:

Sort By:

+ View Data Table

a Diagnosed hypertension defined as adult with self-reported diagnosis, measured blood pressure ≥140/≥90 mmHg and taking hypertension medication; undiagnosed defined as measured blood pressure ≥140/≥90 mmHg without self-reported diagnosis and not taking medication for hypertension; pre-hypertension defined as 120≤SBP≤140/80≤DBP≤90 mmHg. For participants who did not self-report hypertension or were not on medications, exam values for systolic and diastolic blood pressure were used to determine the category of hypertension; No hypertension: SBP <120 and DBP <80 mmHg, Pre-Hypertension: 120≤SBP≤140 mmHg and DBP ≤90 or SBP <120 mmHg and 80≤DBP≤90 mmHg, Hypertension: SBP>140 or DBP>90mmHg.

Prevalence of CKD in diagnosed hypertension remained relatively the same 1999-2004 (29%) to 2011-2018 (28%). During this period, prevalence decreased among undiagnosed (23% to 15%) adults..

Chart Explanation: 

 During the period 1999-2004 to 2011-2018, prevalence of CKD varied based on hypertension status. Among adults with diagnosed hypertension, prevalence decreased from 29.1% in 1999-2004 to 27.6% in 2011-2018. Prevalence among undiagnosed hypertensive adults decreased from 23.1% to 14.6%. Among those found to have pre-hypertension, the prevalence slightly decreased from 8.7% in 1999-2004 to 8.0% in 2011-2018. 

The NHANES surveys are currently conducted every 2 years by the CDC's National Center for Health Statistics to examine disease prevalence and trends over time in different cross-sectional representative samples of noninstitutionalized U.S. civilian residents. The survey consists of a standardized in-home interview and a physical examination and blood and urine collection at a mobile examination center (MEC). Here we examined data from the 1999-2000, 2001-2002, 2003-2004, 2005-2006, 2007-2008, 2009-2010, 2011-2012, and 2013-2014, 2015-2016, and 2017-2018 NHANES. CKD was diagnosed by laboratory testing and defined as an eGFR of ≥60 ml/min/1.73 m2 and the presence of albuminuria (first single measurement of albumin:creatinine ratio from random spot urine) or by eGFR alone for CKD stage 3 or 4 (stage 5 was excluded).

Hypertension is the second leading cause of CKD. Hypertensive disease accounts for 28% of incident ESRD in the United States (United States Renal Data System, 2011). Hypertension is associated with higher risk of cardiovascular outcomes in those with CKD. Additionally, treatment of hypertension in CKD, particularly by ACE inhibitors, has been shown to decrease proteinuria and disease progression (Sarafidis et al., 2008). Thus, assessing the prevalence of this risk factor and its control is essential to CKD surveillance. Self-reported hypertension was defined by answer of “yes” to the question “have you ever been told by a doctor or other health professional that you have hypertension, or high blood pressure?” Blood pressure measurements were taken by standardized protocol during the MEC and the average value (up to four measurements) was used. Hypertension medications were recorded from prescription bottles during the interview.

Description of MeasurePrevalence of CKD in the diagnosed, undiagnosed, and pre-hypertension adult population
Data SourceNCHS/CDC
Type of Data SourcePublic
Health Care System DataNo
Regional or National?National
Demographic GroupNoninstitutionalized U.S. residents aged 20+ years
NumeratorNon-pregnant participants with CKD
DenominatorNon-pregnant participants with response to self-reported hypertension questionnaire, complete blood pressure measurements, and hypertension drug use.
Definition of CKDPresence of single albuminuria or eGFR <60 ml/min/1,73 m2
Glomerular filtration rate

Estimated using CKD-EPI equation for calibrated creatinine: eGFR=141 x [min(calibrated serum creatinine in mg/dL) /κ, 1)]α x [max(calibrated serum creatinine in mg/dL/κ, 1)]-1.209  x 0.993age x (1.018 if female) x (1.159 if NH Black)
κ = 0.7 if female, and 0.9 if male
α = -0.329 if female, and -0.411 if male

ProteinuriaUrinary albumin-to-creatinine ratios of 30-299 mg/g (microalbuminuria) and >300 mg/g (macroalbuminuria); pregnant/menstruating women excluded
Primary Data Source Indicatorbpq020: "Have you ever been told by a doctor or health professional that you have high blood pressure?" yes/no
Primary Indicator Method of MeasurementQuestionnaire (interviewer-administered); ages 16+
Secondary (1) Variablebpxsy1-bpxsy4: Up to four blood pressure measurements
Secondary (1) Indicator Method of MeasurementExamination/Laboratory
Secondary (2) Variablenhcod/rxddrgid; generic drug codes
Secondary (2) Indicator Method of MeasurementQuestionnaire (interviewer-administered), with recording of medications from Rx bottles
Frequency of Measurement (Primary)Once (cross-sectional)
U.S. Region Covered by Primary VariableAll
Period Currently Available


Pending Data


Additional Data Items of InterestStage of CKD, stratification variables of interest (age, gender, race/ethnicity, BMI, diabetes by self-report)
Limitations of IndicatorAlbuminuria and kindey function can only be assessed from a one-time cross-sectional measurement, leading to overestimation of prevalence; second measures of albuminuria are available for only 2009-2010 and were first-morning rather than spot urine samples; no second measures of creatinine
Analytic ConsiderationsAppropriate NHANES survey weights must be used for all analyses; creatinine measurements must be calibrated for 1999-2000 and 2005-2006; many variable names differ across surveys; if SE 30% or more of estimate, must report as "low precision"

Suggested Citation:
Centers for Disease Control and Prevention. Chronic Kidney Disease Surveillance System—United States.
website. http://www.cdc.gov/ckd